http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 19 May 2026 09:53:32 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Corporate+News/BioSyent+receives+Health+Canada+approval+for+levothyroxine+oral+solution/26518886.html <p>BioSyent Inc. (TSX Venture: RX) announced that Health Canada has approved Thyconvi, a levothyroxine oral solution for treating hypothyroidism and thyroid-stimulating hormone suppression. The company states this is the first levothyroxine oral solution available in Canada.</p><p>BioSyent Pharma Inc., a subsidiary of the company, holds exclusive rights to register, market, sell and distribute Thyconvi in Canada. The product contains 20 micrograms of levothyroxine sodium per milliliter and is supplied in packages of two 75-milliliter bottles that do not require refrigeration.</p><p>The oral solution is indicated for hypothyroidism as replacement or supplemental therapy in patients of any age with primary, secondary, and tertiary http://www.streetinsider.com/Corporate+News/BioSyent+receives+Health+Canada+approval+for+levothyroxine+oral+solution/26518886.html Tue, 19 May 2026 09:53:32 -0400 RX http://www.streetinsider.com/Press+Releases/BioSyent+Announces+Health+Canada+Approval+of+Thyconvi%E2%84%A2+%28levothyroxine+oral+solution%29/26518883.html <p align="justify">MISSISSAUGA, Ontario, May 19, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) announces that Health Canada has approved Thyconvi™ (levothyroxine sodium), the first and only levothyroxine oral solution available in Canada for the management of hypothyroidism and thyroid-stimulating hormone (“TSH”) suppression.</p> <p align="justify">BioSyent Pharma Inc., a subsidiary of the Company, has an exclusive license right to register, market, sell and distribute Thyconvi™ in Canada.</p> <p align="justify">“Having a liquid oral levothyroxine option in Canada is a meaningful step forward for hypothyroidism care,” said Dr. Afshan Zahedi, endocrinologist and Medical Director of the Thyroid Program http://www.streetinsider.com/Press+Releases/BioSyent+Announces+Health+Canada+Approval+of+Thyconvi%E2%84%A2+%28levothyroxine+oral+solution%29/26518883.html Tue, 19 May 2026 09:52:00 -0400 A.17150087 A.36078215 A.50208808 A.60012013 O.02555813 O.02597433 O.14730341 O.34929518 O.54379156 RX http://www.streetinsider.com/Press+Releases/BioSyent+Announces+Health+Canada+Approval+of+Thyconvi%E2%84%A2+%28levothyroxine+oral+solution%29/26518883.html <p align="justify">MISSISSAUGA, Ontario, May 19, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) announces that Health Canada has approved Thyconvi™ (levothyroxine sodium), the first and only levothyroxine oral solution available in Canada for the management of hypothyroidism and thyroid-stimulating hormone (“TSH”) suppression.</p> <p align="justify">BioSyent Pharma Inc., a subsidiary of the Company, has an exclusive license right to register, market, sell and distribute Thyconvi™ in Canada.</p> <p align="justify">“Having a liquid oral levothyroxine option in Canada is a meaningful step forward for hypothyroidism care,” said Dr. Afshan Zahedi, endocrinologist and Medical Director of the Thyroid Program http://www.streetinsider.com/Press+Releases/BioSyent+Announces+Health+Canada+Approval+of+Thyconvi%E2%84%A2+%28levothyroxine+oral+solution%29/26518883.html Tue, 19 May 2026 09:52:00 -0400 A.17150087 A.36078215 A.50208808 A.60012013 O.02555813 O.02597433 O.14730341 O.34929518 O.54379156 RX http://www.streetinsider.com/Press+Releases/BioSyent+Announces+Health+Canada+Approval+of+Thyconvi%E2%84%A2+%28levothyroxine+oral+solution%29/26518883.html <p align="justify">MISSISSAUGA, Ontario, May 19, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) announces that Health Canada has approved Thyconvi™ (levothyroxine sodium), the first and only levothyroxine oral solution available in Canada for the management of hypothyroidism and thyroid-stimulating hormone (“TSH”) suppression.</p> <p align="justify">BioSyent Pharma Inc., a subsidiary of the Company, has an exclusive license right to register, market, sell and distribute Thyconvi™ in Canada.</p> <p align="justify">“Having a liquid oral levothyroxine option in Canada is a meaningful step forward for hypothyroidism care,” said Dr. Afshan Zahedi, endocrinologist and Medical Director of the Thyroid Program http://www.streetinsider.com/Press+Releases/BioSyent+Announces+Health+Canada+Approval+of+Thyconvi%E2%84%A2+%28levothyroxine+oral+solution%29/26518883.html Tue, 19 May 2026 09:52:00 -0400 A.17150087 A.36078215 A.50208808 A.60012013 O.02555813 O.02597433 O.14730341 O.34929518 O.54379156 RX http://www.streetinsider.com/Press+Releases/BioSyent+Announces+Health+Canada+Approval+of+Thyconvi%E2%84%A2+%28levothyroxine+oral+solution%29/26518883.html <p align="justify">MISSISSAUGA, Ontario, May 19, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) announces that Health Canada has approved Thyconvi™ (levothyroxine sodium), the first and only levothyroxine oral solution available in Canada for the management of hypothyroidism and thyroid-stimulating hormone (“TSH”) suppression.</p> <p align="justify">BioSyent Pharma Inc., a subsidiary of the Company, has an exclusive license right to register, market, sell and distribute Thyconvi™ in Canada.</p> <p align="justify">“Having a liquid oral levothyroxine option in Canada is a meaningful step forward for hypothyroidism care,” said Dr. Afshan Zahedi, endocrinologist and Medical Director of the Thyroid Program http://www.streetinsider.com/Press+Releases/BioSyent+Announces+Health+Canada+Approval+of+Thyconvi%E2%84%A2+%28levothyroxine+oral+solution%29/26518883.html Tue, 19 May 2026 09:52:00 -0400 A.17150087 A.36078215 A.50208808 A.60012013 O.02555813 O.02597433 O.14730341 O.34929518 O.54379156 RX http://www.streetinsider.com/Press+Releases/BioSyent+Announces+Health+Canada+Approval+of+Thyconvi%E2%84%A2+%28levothyroxine+oral+solution%29/26518883.html <p align="justify">MISSISSAUGA, Ontario, May 19, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) announces that Health Canada has approved Thyconvi™ (levothyroxine sodium), the first and only levothyroxine oral solution available in Canada for the management of hypothyroidism and thyroid-stimulating hormone (“TSH”) suppression.</p> <p align="justify">BioSyent Pharma Inc., a subsidiary of the Company, has an exclusive license right to register, market, sell and distribute Thyconvi™ in Canada.</p> <p align="justify">“Having a liquid oral levothyroxine option in Canada is a meaningful step forward for hypothyroidism care,” said Dr. Afshan Zahedi, endocrinologist and Medical Director of the Thyroid Program http://www.streetinsider.com/Press+Releases/BioSyent+Announces+Health+Canada+Approval+of+Thyconvi%E2%84%A2+%28levothyroxine+oral+solution%29/26518883.html Tue, 19 May 2026 09:52:00 -0400 A.17150087 A.36078215 A.50208808 A.60012013 O.02555813 O.02597433 O.14730341 O.34929518 O.54379156 RX http://www.streetinsider.com/Press+Releases/BioSyent+Announces+Health+Canada+Approval+of+Thyconvi%E2%84%A2+%28levothyroxine+oral+solution%29/26518883.html <p align="justify">MISSISSAUGA, Ontario, May 19, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) announces that Health Canada has approved Thyconvi™ (levothyroxine sodium), the first and only levothyroxine oral solution available in Canada for the management of hypothyroidism and thyroid-stimulating hormone (“TSH”) suppression.</p> <p align="justify">BioSyent Pharma Inc., a subsidiary of the Company, has an exclusive license right to register, market, sell and distribute Thyconvi™ in Canada.</p> <p align="justify">“Having a liquid oral levothyroxine option in Canada is a meaningful step forward for hypothyroidism care,” said Dr. Afshan Zahedi, endocrinologist and Medical Director of the Thyroid Program http://www.streetinsider.com/Press+Releases/BioSyent+Announces+Health+Canada+Approval+of+Thyconvi%E2%84%A2+%28levothyroxine+oral+solution%29/26518883.html Tue, 19 May 2026 09:52:00 -0400 A.17150087 A.36078215 A.50208808 A.60012013 O.02555813 O.02597433 O.14730341 O.34929518 O.54379156 RX http://www.streetinsider.com/Press+Releases/BioSyent+Announces+Health+Canada+Approval+of+Thyconvi%E2%84%A2+%28levothyroxine+oral+solution%29/26518883.html <p align="justify">MISSISSAUGA, Ontario, May 19, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) announces that Health Canada has approved Thyconvi™ (levothyroxine sodium), the first and only levothyroxine oral solution available in Canada for the management of hypothyroidism and thyroid-stimulating hormone (“TSH”) suppression.</p> <p align="justify">BioSyent Pharma Inc., a subsidiary of the Company, has an exclusive license right to register, market, sell and distribute Thyconvi™ in Canada.</p> <p align="justify">“Having a liquid oral levothyroxine option in Canada is a meaningful step forward for hypothyroidism care,” said Dr. Afshan Zahedi, endocrinologist and Medical Director of the Thyroid Program http://www.streetinsider.com/Press+Releases/BioSyent+Announces+Health+Canada+Approval+of+Thyconvi%E2%84%A2+%28levothyroxine+oral+solution%29/26518883.html Tue, 19 May 2026 09:52:00 -0400 A.17150087 A.36078215 A.50208808 A.60012013 O.02555813 O.02597433 O.14730341 O.34929518 O.54379156 RX http://www.streetinsider.com/Press+Releases/BioSyent+Announces+Health+Canada+Approval+of+Thyconvi%E2%84%A2+%28levothyroxine+oral+solution%29/26518883.html <p align="justify">MISSISSAUGA, Ontario, May 19, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) announces that Health Canada has approved Thyconvi™ (levothyroxine sodium), the first and only levothyroxine oral solution available in Canada for the management of hypothyroidism and thyroid-stimulating hormone (“TSH”) suppression.</p> <p align="justify">BioSyent Pharma Inc., a subsidiary of the Company, has an exclusive license right to register, market, sell and distribute Thyconvi™ in Canada.</p> <p align="justify">“Having a liquid oral levothyroxine option in Canada is a meaningful step forward for hypothyroidism care,” said Dr. Afshan Zahedi, endocrinologist and Medical Director of the Thyroid Program http://www.streetinsider.com/Press+Releases/BioSyent+Announces+Health+Canada+Approval+of+Thyconvi%E2%84%A2+%28levothyroxine+oral+solution%29/26518883.html Tue, 19 May 2026 09:52:00 -0400 A.17150087 A.36078215 A.50208808 A.60012013 O.02555813 O.02597433 O.14730341 O.34929518 O.54379156 RX http://www.streetinsider.com/Press+Releases/BioSyent+Announces+Health+Canada+Approval+of+Thyconvi%E2%84%A2+%28levothyroxine+oral+solution%29/26518883.html <p align="justify">MISSISSAUGA, Ontario, May 19, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) announces that Health Canada has approved Thyconvi™ (levothyroxine sodium), the first and only levothyroxine oral solution available in Canada for the management of hypothyroidism and thyroid-stimulating hormone (“TSH”) suppression.</p> <p align="justify">BioSyent Pharma Inc., a subsidiary of the Company, has an exclusive license right to register, market, sell and distribute Thyconvi™ in Canada.</p> <p align="justify">“Having a liquid oral levothyroxine option in Canada is a meaningful step forward for hypothyroidism care,” said Dr. Afshan Zahedi, endocrinologist and Medical Director of the Thyroid Program http://www.streetinsider.com/Press+Releases/BioSyent+Announces+Health+Canada+Approval+of+Thyconvi%E2%84%A2+%28levothyroxine+oral+solution%29/26518883.html Tue, 19 May 2026 09:52:00 -0400 A.17150087 A.36078215 A.50208808 A.60012013 O.02555813 O.02597433 O.14730341 O.34929518 O.54379156 RX http://www.streetinsider.com/Press+Releases/BioSyent+Announces+Health+Canada+Approval+of+Thyconvi%E2%84%A2+%28levothyroxine+oral+solution%29/26518883.html <p align="justify">MISSISSAUGA, Ontario, May 19, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) announces that Health Canada has approved Thyconvi™ (levothyroxine sodium), the first and only levothyroxine oral solution available in Canada for the management of hypothyroidism and thyroid-stimulating hormone (“TSH”) suppression.</p> <p align="justify">BioSyent Pharma Inc., a subsidiary of the Company, has an exclusive license right to register, market, sell and distribute Thyconvi™ in Canada.</p> <p align="justify">“Having a liquid oral levothyroxine option in Canada is a meaningful step forward for hypothyroidism care,” said Dr. Afshan Zahedi, endocrinologist and Medical Director of the Thyroid Program http://www.streetinsider.com/Press+Releases/BioSyent+Announces+Health+Canada+Approval+of+Thyconvi%E2%84%A2+%28levothyroxine+oral+solution%29/26518883.html Tue, 19 May 2026 09:52:00 -0400 A.17150087 A.36078215 A.50208808 A.60012013 O.02555813 O.02597433 O.14730341 O.34929518 O.54379156 RX http://www.streetinsider.com/Globe+Newswire/BioSyent+Announces+Health+Canada+Approval+of+Thyconvi%E2%84%A2+%28levothyroxine+oral+solution%29/26518883.html <p align="justify">MISSISSAUGA, Ontario, May 19, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) announces that Health Canada has approved Thyconvi™ (levothyroxine sodium), the first and only levothyroxine oral solution available in Canada for the management of hypothyroidism and thyroid-stimulating hormone (“TSH”) suppression.</p> <p align="justify">BioSyent Pharma Inc., a subsidiary of the Company, has an exclusive license right to register, market, sell and distribute Thyconvi™ in Canada.</p> <p align="justify">“Having a liquid oral levothyroxine option in Canada is a meaningful step forward for hypothyroidism care,” said Dr. Afshan Zahedi, endocrinologist and Medical Director of the Thyroid Program http://www.streetinsider.com/Globe+Newswire/BioSyent+Announces+Health+Canada+Approval+of+Thyconvi%E2%84%A2+%28levothyroxine+oral+solution%29/26518883.html Tue, 19 May 2026 09:52:00 -0400 A.17150087 A.36078215 A.50208808 A.60012013 O.02555813 O.02597433 O.14730341 O.34929518 O.54379156 RX http://www.streetinsider.com/Globe+Newswire/BioSyent+Announces+Health+Canada+Approval+of+Thyconvi%E2%84%A2+%28levothyroxine+oral+solution%29/26518883.html <p align="justify">MISSISSAUGA, Ontario, May 19, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) announces that Health Canada has approved Thyconvi™ (levothyroxine sodium), the first and only levothyroxine oral solution available in Canada for the management of hypothyroidism and thyroid-stimulating hormone (“TSH”) suppression.</p> <p align="justify">BioSyent Pharma Inc., a subsidiary of the Company, has an exclusive license right to register, market, sell and distribute Thyconvi™ in Canada.</p> <p align="justify">“Having a liquid oral levothyroxine option in Canada is a meaningful step forward for hypothyroidism care,” said Dr. Afshan Zahedi, endocrinologist and Medical Director of the Thyroid Program http://www.streetinsider.com/Globe+Newswire/BioSyent+Announces+Health+Canada+Approval+of+Thyconvi%E2%84%A2+%28levothyroxine+oral+solution%29/26518883.html Tue, 19 May 2026 09:52:00 -0400 A.17150087 A.36078215 A.50208808 A.60012013 O.02555813 O.02597433 O.14730341 O.34929518 O.54379156 RX http://www.streetinsider.com/Globe+Newswire/BioSyent+Announces+Health+Canada+Approval+of+Thyconvi%E2%84%A2+%28levothyroxine+oral+solution%29/26518883.html <p align="justify">MISSISSAUGA, Ontario, May 19, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) announces that Health Canada has approved Thyconvi™ (levothyroxine sodium), the first and only levothyroxine oral solution available in Canada for the management of hypothyroidism and thyroid-stimulating hormone (“TSH”) suppression.</p> <p align="justify">BioSyent Pharma Inc., a subsidiary of the Company, has an exclusive license right to register, market, sell and distribute Thyconvi™ in Canada.</p> <p align="justify">“Having a liquid oral levothyroxine option in Canada is a meaningful step forward for hypothyroidism care,” said Dr. Afshan Zahedi, endocrinologist and Medical Director of the Thyroid Program http://www.streetinsider.com/Globe+Newswire/BioSyent+Announces+Health+Canada+Approval+of+Thyconvi%E2%84%A2+%28levothyroxine+oral+solution%29/26518883.html Tue, 19 May 2026 09:52:00 -0400 A.17150087 A.36078215 A.50208808 A.60012013 O.02555813 O.02597433 O.14730341 O.34929518 O.54379156 RX http://www.streetinsider.com/Globe+Newswire/BioSyent+Announces+Health+Canada+Approval+of+Thyconvi%E2%84%A2+%28levothyroxine+oral+solution%29/26518883.html <p align="justify">MISSISSAUGA, Ontario, May 19, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) announces that Health Canada has approved Thyconvi™ (levothyroxine sodium), the first and only levothyroxine oral solution available in Canada for the management of hypothyroidism and thyroid-stimulating hormone (“TSH”) suppression.</p> <p align="justify">BioSyent Pharma Inc., a subsidiary of the Company, has an exclusive license right to register, market, sell and distribute Thyconvi™ in Canada.</p> <p align="justify">“Having a liquid oral levothyroxine option in Canada is a meaningful step forward for hypothyroidism care,” said Dr. Afshan Zahedi, endocrinologist and Medical Director of the Thyroid Program http://www.streetinsider.com/Globe+Newswire/BioSyent+Announces+Health+Canada+Approval+of+Thyconvi%E2%84%A2+%28levothyroxine+oral+solution%29/26518883.html Tue, 19 May 2026 09:52:00 -0400 A.17150087 A.36078215 A.50208808 A.60012013 O.02555813 O.02597433 O.14730341 O.34929518 O.54379156 RX http://www.streetinsider.com/Globe+Newswire/BioSyent+Announces+Health+Canada+Approval+of+Thyconvi%E2%84%A2+%28levothyroxine+oral+solution%29/26518883.html <p align="justify">MISSISSAUGA, Ontario, May 19, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) announces that Health Canada has approved Thyconvi™ (levothyroxine sodium), the first and only levothyroxine oral solution available in Canada for the management of hypothyroidism and thyroid-stimulating hormone (“TSH”) suppression.</p> <p align="justify">BioSyent Pharma Inc., a subsidiary of the Company, has an exclusive license right to register, market, sell and distribute Thyconvi™ in Canada.</p> <p align="justify">“Having a liquid oral levothyroxine option in Canada is a meaningful step forward for hypothyroidism care,” said Dr. Afshan Zahedi, endocrinologist and Medical Director of the Thyroid Program http://www.streetinsider.com/Globe+Newswire/BioSyent+Announces+Health+Canada+Approval+of+Thyconvi%E2%84%A2+%28levothyroxine+oral+solution%29/26518883.html Tue, 19 May 2026 09:52:00 -0400 A.17150087 A.36078215 A.50208808 A.60012013 O.02555813 O.02597433 O.14730341 O.34929518 O.54379156 RX http://www.streetinsider.com/Globe+Newswire/BioSyent+Announces+Health+Canada+Approval+of+Thyconvi%E2%84%A2+%28levothyroxine+oral+solution%29/26518883.html <p align="justify">MISSISSAUGA, Ontario, May 19, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) announces that Health Canada has approved Thyconvi™ (levothyroxine sodium), the first and only levothyroxine oral solution available in Canada for the management of hypothyroidism and thyroid-stimulating hormone (“TSH”) suppression.</p> <p align="justify">BioSyent Pharma Inc., a subsidiary of the Company, has an exclusive license right to register, market, sell and distribute Thyconvi™ in Canada.</p> <p align="justify">“Having a liquid oral levothyroxine option in Canada is a meaningful step forward for hypothyroidism care,” said Dr. Afshan Zahedi, endocrinologist and Medical Director of the Thyroid Program http://www.streetinsider.com/Globe+Newswire/BioSyent+Announces+Health+Canada+Approval+of+Thyconvi%E2%84%A2+%28levothyroxine+oral+solution%29/26518883.html Tue, 19 May 2026 09:52:00 -0400 A.17150087 A.36078215 A.50208808 A.60012013 O.02555813 O.02597433 O.14730341 O.34929518 O.54379156 RX http://www.streetinsider.com/Globe+Newswire/BioSyent+Announces+Health+Canada+Approval+of+Thyconvi%E2%84%A2+%28levothyroxine+oral+solution%29/26518883.html <p align="justify">MISSISSAUGA, Ontario, May 19, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) announces that Health Canada has approved Thyconvi™ (levothyroxine sodium), the first and only levothyroxine oral solution available in Canada for the management of hypothyroidism and thyroid-stimulating hormone (“TSH”) suppression.</p> <p align="justify">BioSyent Pharma Inc., a subsidiary of the Company, has an exclusive license right to register, market, sell and distribute Thyconvi™ in Canada.</p> <p align="justify">“Having a liquid oral levothyroxine option in Canada is a meaningful step forward for hypothyroidism care,” said Dr. Afshan Zahedi, endocrinologist and Medical Director of the Thyroid Program http://www.streetinsider.com/Globe+Newswire/BioSyent+Announces+Health+Canada+Approval+of+Thyconvi%E2%84%A2+%28levothyroxine+oral+solution%29/26518883.html Tue, 19 May 2026 09:52:00 -0400 A.17150087 A.36078215 A.50208808 A.60012013 O.02555813 O.02597433 O.14730341 O.34929518 O.54379156 RX http://www.streetinsider.com/Globe+Newswire/BioSyent+Announces+Health+Canada+Approval+of+Thyconvi%E2%84%A2+%28levothyroxine+oral+solution%29/26518883.html <p align="justify">MISSISSAUGA, Ontario, May 19, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) announces that Health Canada has approved Thyconvi™ (levothyroxine sodium), the first and only levothyroxine oral solution available in Canada for the management of hypothyroidism and thyroid-stimulating hormone (“TSH”) suppression.</p> <p align="justify">BioSyent Pharma Inc., a subsidiary of the Company, has an exclusive license right to register, market, sell and distribute Thyconvi™ in Canada.</p> <p align="justify">“Having a liquid oral levothyroxine option in Canada is a meaningful step forward for hypothyroidism care,” said Dr. Afshan Zahedi, endocrinologist and Medical Director of the Thyroid Program http://www.streetinsider.com/Globe+Newswire/BioSyent+Announces+Health+Canada+Approval+of+Thyconvi%E2%84%A2+%28levothyroxine+oral+solution%29/26518883.html Tue, 19 May 2026 09:52:00 -0400 A.17150087 A.36078215 A.50208808 A.60012013 O.02555813 O.02597433 O.14730341 O.34929518 O.54379156 RX http://www.streetinsider.com/Globe+Newswire/BioSyent+Announces+Health+Canada+Approval+of+Thyconvi%E2%84%A2+%28levothyroxine+oral+solution%29/26518883.html <p align="justify">MISSISSAUGA, Ontario, May 19, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) announces that Health Canada has approved Thyconvi™ (levothyroxine sodium), the first and only levothyroxine oral solution available in Canada for the management of hypothyroidism and thyroid-stimulating hormone (“TSH”) suppression.</p> <p align="justify">BioSyent Pharma Inc., a subsidiary of the Company, has an exclusive license right to register, market, sell and distribute Thyconvi™ in Canada.</p> <p align="justify">“Having a liquid oral levothyroxine option in Canada is a meaningful step forward for hypothyroidism care,” said Dr. Afshan Zahedi, endocrinologist and Medical Director of the Thyroid Program http://www.streetinsider.com/Globe+Newswire/BioSyent+Announces+Health+Canada+Approval+of+Thyconvi%E2%84%A2+%28levothyroxine+oral+solution%29/26518883.html Tue, 19 May 2026 09:52:00 -0400 A.17150087 A.36078215 A.50208808 A.60012013 O.02555813 O.02597433 O.14730341 O.34929518 O.54379156 RX http://www.streetinsider.com/Globe+Newswire/BioSyent+Announces+Health+Canada+Approval+of+Thyconvi%E2%84%A2+%28levothyroxine+oral+solution%29/26518883.html <p align="justify">MISSISSAUGA, Ontario, May 19, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) announces that Health Canada has approved Thyconvi™ (levothyroxine sodium), the first and only levothyroxine oral solution available in Canada for the management of hypothyroidism and thyroid-stimulating hormone (“TSH”) suppression.</p> <p align="justify">BioSyent Pharma Inc., a subsidiary of the Company, has an exclusive license right to register, market, sell and distribute Thyconvi™ in Canada.</p> <p align="justify">“Having a liquid oral levothyroxine option in Canada is a meaningful step forward for hypothyroidism care,” said Dr. Afshan Zahedi, endocrinologist and Medical Director of the Thyroid Program http://www.streetinsider.com/Globe+Newswire/BioSyent+Announces+Health+Canada+Approval+of+Thyconvi%E2%84%A2+%28levothyroxine+oral+solution%29/26518883.html Tue, 19 May 2026 09:52:00 -0400 A.17150087 A.36078215 A.50208808 A.60012013 O.02555813 O.02597433 O.14730341 O.34929518 O.54379156 RX http://www.streetinsider.com/Press+Releases/BioSyent+Declares+Second+Quarter+2026+Dividend/26497056.html <p align="justify">MISSISSAUGA, Ontario, May 14, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its Board of Directors has declared a quarterly dividend of $0.055 per common share, payable in Canadian Dollars on June 15, 2026, to shareholders of record at the close of business on May 29, 2026. This second quarter 2026 dividend compares to a first quarter dividend of $0.055 per common share. This dividend qualifies as an &apos;eligible dividend&apos; for Canadian income tax purposes. The declaration, timing, amount and payment of future dividends remain at the discretion http://www.streetinsider.com/Press+Releases/BioSyent+Declares+Second+Quarter+2026+Dividend/26497056.html Thu, 14 May 2026 18:01:00 -0400 A.36078215 O.02555813 O.02597433 RX http://www.streetinsider.com/Press+Releases/BioSyent+Declares+Second+Quarter+2026+Dividend/26497056.html <p align="justify">MISSISSAUGA, Ontario, May 14, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its Board of Directors has declared a quarterly dividend of $0.055 per common share, payable in Canadian Dollars on June 15, 2026, to shareholders of record at the close of business on May 29, 2026. This second quarter 2026 dividend compares to a first quarter dividend of $0.055 per common share. This dividend qualifies as an &apos;eligible dividend&apos; for Canadian income tax purposes. The declaration, timing, amount and payment of future dividends remain at the discretion http://www.streetinsider.com/Press+Releases/BioSyent+Declares+Second+Quarter+2026+Dividend/26497056.html Thu, 14 May 2026 18:01:00 -0400 A.36078215 O.02555813 O.02597433 RX http://www.streetinsider.com/Press+Releases/BioSyent+Declares+Second+Quarter+2026+Dividend/26497056.html <p align="justify">MISSISSAUGA, Ontario, May 14, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its Board of Directors has declared a quarterly dividend of $0.055 per common share, payable in Canadian Dollars on June 15, 2026, to shareholders of record at the close of business on May 29, 2026. This second quarter 2026 dividend compares to a first quarter dividend of $0.055 per common share. This dividend qualifies as an &apos;eligible dividend&apos; for Canadian income tax purposes. The declaration, timing, amount and payment of future dividends remain at the discretion http://www.streetinsider.com/Press+Releases/BioSyent+Declares+Second+Quarter+2026+Dividend/26497056.html Thu, 14 May 2026 18:01:00 -0400 A.36078215 O.02555813 O.02597433 RX http://www.streetinsider.com/Press+Releases/BioSyent+Declares+Second+Quarter+2026+Dividend/26497056.html <p align="justify">MISSISSAUGA, Ontario, May 14, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its Board of Directors has declared a quarterly dividend of $0.055 per common share, payable in Canadian Dollars on June 15, 2026, to shareholders of record at the close of business on May 29, 2026. This second quarter 2026 dividend compares to a first quarter dividend of $0.055 per common share. This dividend qualifies as an &apos;eligible dividend&apos; for Canadian income tax purposes. The declaration, timing, amount and payment of future dividends remain at the discretion http://www.streetinsider.com/Press+Releases/BioSyent+Declares+Second+Quarter+2026+Dividend/26497056.html Thu, 14 May 2026 18:01:00 -0400 A.36078215 O.02555813 O.02597433 RX